Our top pick for
Abcam plc is a biotechnology business based in the US. Abcam shares (ABCM) are listed on the NASDAQ and all prices are listed in US Dollars. Abcam employs 1,492 staff and has a market cap (total outstanding shares value) of USD$5.3 billion.
|52-week range||USD$17.71 - USD$24.69|
|50-day moving average||USD$22.7676|
|200-day moving average||USD$20.7611|
|Wall St. target price||USD$1636.24|
|Dividend yield||USD$0.15 (0.66%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Abcam stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abcam's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 240x. In other words, Abcam shares trade at around 240x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Abcam's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
|Gross profit TTM||USD$180.2 million|
|Return on assets TTM||4.42%|
|Return on equity TTM||2.82%|
|Market capitalisation||USD$5.3 billion|
TTM: trailing 12 months
There are currently 243,603 Abcam shares held short by investors – that's known as Abcam's "short interest". This figure is 1.4% up from 240,320 last month.
There are a few different ways that this level of interest in shorting Abcam shares can be evaluated.
Abcam's "short interest ratio" (SIR) is the quantity of Abcam shares currently shorted divided by the average quantity of Abcam shares traded daily (recently around 243603). Abcam's SIR currently stands at 1. In other words for every 100,000 Abcam shares traded daily on the market, roughly 1000 shares are currently held short.
To gain some more context, you can compare Abcam's short interest ratio against those of similar companies.
However Abcam's short interest can also be evaluated against the total number of Abcam shares, or, against the total number of tradable Abcam shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abcam's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Abcam shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Abcam shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abcam.
Find out more about how you can short Abcam stock.
Dividend payout ratio: 202.68% of net profits
Recently Abcam has paid out, on average, around 202.68% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abcam shareholders could enjoy a 0.66% return on their shares, in the form of dividend payments. In Abcam's case, that would currently equate to about $0.15 per share.
Abcam's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 19 March 2020 (the "ex-dividend date").
Abcam's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Abcam's shares have ranged in value from as little as $17.71 up to $24.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcam's is 0.4005. This would suggest that Abcam's shares are less volatile than average (for this exchange).
To put Abcam's beta into context you can compare it against those of similar companies.
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.